The Effect of Various KRAS Mutations on NSCLC Susceptibility

2021 Year in Review: Non–Small-Cell Lung Cancer —December 29, 2021

Categories:

Lung Cancer

The oncogenic driver, KRAS, is the most frequent mutation in patients with non–small-cell lung cancer (NSCLC).1 According to research, only KRAS mutations and KRAS mutations in combination with STK11 define separate NSCLC subgroups that respond differently to immune checkpoint inhibitors.1

Previous efforts to find therapeutics to offset the oncogenic effects of KRAS mutations have mostly failed, and malignancies caused by KRAS have been among the most resistant to treatments.2 A study was undertaken in China between May 2017 and May 2020 to investigate the mechanism of immune checkpoint inhibitor efficacy in these subgroups of Chinese patients with NSCLC by analyzing the tumor immune microenvironment and a number of biomarkers.1

This study comprised formalin-fixed paraffin-embedded specimens from patients with cancer who underwent next-generation sequencing. Next-generation sequencing was used to detect gene mutations, and a 733-gene panel was used to determine tumor mutational burden (TMB).

A total of 3323 Chinese patients with NSCLC were admitted for next-generation sequencing and tumor immune microenvironment analysis, with 1002 samples accessible for TMB analysis, 796 samples for PD-L1 expression analysis, and 19 samples available for tumor immune microenvironment evaluation. Three subgroups were identified: those with only KRAS mutations, those with only STK11 mutations, and those with both KRAS and STK11 mutations. The median TMB level in the co-mutation group was slightly lower than in the other groups, but there was no significant difference in the TMB levels of the 3 subgroups. The amount of PD-L1 expression in the KRAS mutant group was considerably higher than in the STK11 mutation or co-mutation groups (P <.001). Furthermore, multiple immunohistochemistry demonstrated that the number of positive immune cells infiltrating the tumors in the STK11 and co-mutation groups was lower than in the KRAS mutation group.1

KRAS mutation–positive cancers come in a wide variety of shapes and sizes. The type of KRAS variation and existence of co-mutations have an impact on the biology of KRAS-driven illnesses.3 The study in China showed that the variation in the tumor immune microenvironment, which includes immune cell infiltrated and PD-L1 expression, can explain the divergent response to immune checkpoint inhibitors in patients with KRAS mutation and STK11 co-mutation.1 Although the treatment environment has shifted substantially, combination trials are still ongoing. Understanding the biology of resistance mechanisms is a fundamental strategy to improve the medicines available to patients.3

References

  1. Wang K, Zhang H, Xu H, et al. Differences of immune microenvironment among NSCLC patients with various KRAS mutation types. Ann Oncol. 2021;32(suppl 5):S983.
  2. Westcott PMK, To MD. The genetics and biology of KRAS in lung cancer. Chin J Cancer. 2013;32:63-70.
  3. Addeo A, Banna GL, Friedlaender A. KRAS G12C mutations in NSCLC: from target to resistance. Cancers (Basel). 2021;13:2541.
Related Articles
Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country